Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial

Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial Elmwood Park, New Jersey, June 17, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single - Dose Vial . Glenmark’s Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue®2 Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630]. According to IQVIA® sales data for the 12 -month period ending April 2026, the ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL) market3 achieved annual sales of approximately $19.0 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Methylene Blue Injection USP reflects Glenmark’s ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio a nd reinforces our focus on delivering reliable treatment options across the U.S. market.” 1Glenmark’s Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single -Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label. 2All brand names and trademarks are the property of their respective owners. 3Market includes brand and all available therapeutic equivalents. Note: IQVIA ® data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for and will only be marketed for the indications listed in Glenmark’s approved label, which may be different than the approved RLD indications. *IQVIA® National Sales Perspectives: Retail & Non-Retail, April 2026 About Glenmark Pharmaceuticals Limited: Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research ‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. W ith 11 world -class manufacturing facilities across four continents, supported by six cutting -edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health product s, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com. For more information, please contact: India United States Akhila Natarajan [email protected] +91 22 4018 9999 Adfactors PR [email protected] Akhila Natarajan [email protected] Danielle Hagen [email protected] 202-365-6112

The release as fetched from its publisher. glenmarkpharma.com ↗